Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 1942-1948

  Clouser, Christine L ^a   Holtz, Colleen M ^a,b   Mullett, Mary ^f   Crankshaw, Daune L ^f   Briggs, Jacquie E ^f   O'Sullivan, M Gerard ^e,g   Patterson, Steven E ^a,c   Mansky, Louis M ^a,b,c,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f VA MEDICAL CENTER   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GEMCITABINE; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; BODY WEIGHT; CELL CULTURE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG POTENCY; FEMALE; HISTOPATHOLOGY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; LOW DRUG DOSE; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVIRUS; SPLEEN WEIGHT; SPLENOMEGALY; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; AZACITIDINE; BODY WEIGHT; CELLS, CULTURED; DEOXYCYTIDINE; DRUG COMBINATIONS; DRUG SYNERGISM; DRUG-INDUCED LIVER INJURY; FEMALE; FLOW CYTOMETRY; HIV-1; HUMANS; LIVER; LYMPH NODES; MICE; MICE, INBRED C57BL; MURINE ACQUIRED IMMUNODEFICIENCY SYNDROME; PROVIRUSES; SPLEEN; T-LYMPHOCYTES; TRANSFECTION;

EID: 84858665496     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06161-11     Document Type: Article

References (30)

1. Bartz SR, Vodicka MA. 1997. Production of high-titer human immunodeficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein. Methods 12:337-342. (Pubitemid 27371258)
2. Bebenek K, Roberts JD, Kunkel TA. 1992. The effects of dNTP pool imbalances on frameshift fidelity during DNA replication. J. Biol. Chem. 267:3589-3596.
3. Boyer PL, et al. 2001. YADD mutants of human immunodeficiency virus type 1 and Moloney murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphate (3TCTP) in vitro. J. Virol. 75:6321-6328. (Pubitemid 32578150)
4. Bull JJ, Sanjuán R, Wilke CO. 2007. Theory of lethal mutagenesis for viruses. J. Virol. 81:2930-2939. (Pubitemid 46447056)
5. Casabianca A, Orlandi C, Fraternale A, Magnani M. 2004. Development of a real-time PCR assay using SYBR green for provirus load quantification in a murine model of AIDS. J. Clin. Microbiol. 42:4361-4364. (Pubitemid 39296178)
6. Chattopadhyay SK, Morse HCI, Makino M, Ruscetti SK, Hartley JW. 1989. Defective virus is associated with induction of murine retrovirus-induced immunodeficiency syndrome. Proc. Natl. Acad. Sci. U. S. A. 86: 3862-3866. (Pubitemid 19141845)
7. Clouser CL, et al. 2011. Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine. PLoS One 6:e15840.
8. Clouser CL, Patterson SE, Mansky LM. 2010. Exploiting drug repositioning for discovery of a novel HIV combination therapy. J. Virol. 84: 9301-9309.
9. Dapp MJ, Clouser CL, Patterson S, Mansky LM. 2009. 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. J. Virol. 83:11950-11958.
10. Dias AS, Bester MJ, Britz RF, Apostolides Z. 2006. Animal models used for the evaluation of antiretroviral therapies. Curr. HIV Res. 4:431-446. (Pubitemid 44524444)
11. Elion GB, Singer S, Hitchings GH. 1954. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J. Biol. Chem. 208:477-488.
12. Graci JD, et al. 2007. Lethal mutagenesis of poliovirus mediated by a mutagenic pyrimidine analogue. J. Virol. 81:11256-11266. (Pubitemid 47536098)
13. Hall MJ, Middleton RF, Westmacott D. 1983. The fractional inhibitory concentration (FIC) index as a measure of synergy. J. Antimicrob. Chemother. 11:427-433. (Pubitemid 13094077)
14. Harrington RD, Geballe AP. 1993. Cofactor requirement for human immunodeficiency virus type 1 entry into a CD4-expressing human cell line. J. Virol. 67:5939-5947. (Pubitemid 23277504)
15. Hartley JW, Fredrickson TN, Yetter RA, Makino M, Morse HCI. 1989. Retrovirus-induced murine acquired immunodeficiency syndrome: natural history of infection and differing susceptibility of inbred mouse strains. J. Virol. 63:1223-1231. (Pubitemid 19061364)
16. Jolicoeur P. 1991. Murine acquired immunodeficiency syndrome (MAIDS): an animal model to study the AIDS pathogenesis. FASEB J. 5:2398-2405. (Pubitemid 21905787)
17. Lavelle D, et al. 2007. Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis. Am. J. Hematol. 82:981-985. (Pubitemid 350004389)
18. Loeb LA, et al. 1999. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc. Natl. Acad. Sci. U. S. A. 96:1492-1497. (Pubitemid 29098478)
19. Mezei M, Minarovits J. 2006. Reversal of HIV drug resistance and novel strategies to curb HIV infection: the viral infectivity factor Vif as a target and tool of therapy. Curr. Drug Targets 7:881-885.
20. Morse HCI, et al. 1992. Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS. AIDS 6:607-621.
21. Ohnota H, et al. 1990. 3′-Azido-3′-deoxythymidine prevents induction of murine acquired immunodeficiency syndrome in C57BL/10 mice infected with LP-BM5 murine leukemia viruses, a possible animal model for antiretroviral drug screening. Antimicrob. Agents Chemother. 34:605-609. (Pubitemid 20122290)
22. Pear WS, et al. 1998. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92:3780-3792. (Pubitemid 28525205)
23. Reagan-Shaw S, Nihal M, Ahmad N. 2008. Dose translation from animal to human studies revisited. FASEB J. 22:659-661. (Pubitemid 351348146)
24. Rossi L, et al. 1993. Inhibition of murine retrovirus-induced immunodeficiency disease by dideoxycytidine and dideoxycytidine 5′- triphosphate. J. Acquir. Immune Defic. Syndr. 6:1179-1186. (Pubitemid 23314392)
25. Rossi L, et al. 2002. Inhibition of murine AIDS by a heterodinucleotide of azidothymidine and 9-(R)-2-(phosphonomethoxypropyl)adenine. J. Antimicrob. Chemother. 50:639-647. (Pubitemid 35331680)
26. Sakamoto H, et al. 2006. Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial. J. Gastroenterol. 41:70-76.
27. Smith RA, Loeb LA, Preston BD. 2005. Lethal mutagenesis of HIV. Virus Res. 107:215-228. (Pubitemid 40093094)
28. Smith RA, Remington KM, Lloyd JRM, Schinazi RF, North TW. 1997. A novel Met-to-Thr mutation in theYMDDmotif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides. J. Virol. 71:2357-2362. (Pubitemid 27078618)
29. Vodicka MA, et al. 1997. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 233: 193-198. (Pubitemid 27348781)
30. + T cells are required for development of a murine retrovirus-induced immunodeficiency syndrome (MAIDS). J. Exp. Med. 168:623-635.